Nasdaq · CIK 0001177648
ENTA ENANTA PHARMACEUTICALS INC
Insider trading from SEC Form 4. Last filing Mar 14, 2025. Close $12.50 on Oct 9, 2026, +19% from the 52-week low and -26% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
ENTAOct 9, 2026 · close 12.50
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ENANTA PHARMACEUTICALS INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | Jay R. Luly President and CEO buy | $256k 45,000 shares | +6% | - | |
| 26Weak | Jay R. Luly President and CEO sell | $41k 5,142 shares | -1% | - | |
| 17Weak | Paul J Mellett Chief Fin. & Admin Officer sell | $21k 2,591 shares | -3% | - | |
| 10Weak | Yat Sun Or Chief Scientific Officer sell | $21k 2,591 shares | -1% | - | |
| 10Weak | Scott T. Rottinghaus Chief Medical Officer sell | $6,980 866 shares | -5% | - | |
| 10Weak | Brendan Luu Chief Business Officer sell | $18k 2,283 shares | -6% | - | |
| 10Weak | Tara Lynn Kieffer Chief Product Strategy Officer sell | $18k 2,283 shares | -7% | - |
Transactions
The last 37 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 13, 2025 | Mark G Foletta director | AGrant or award Stock Option (right to buy)derivative | +15,700 | $0.00 | $0 | 15,700 | Mar 14, 2025 |
| Mar 13, 2025 | Yujiro S Hata director | AGrant or award Stock Option (right to buy)derivative | +15,700 | $0.00 | $0 | 15,700 | Mar 14, 2025 |
| Mar 13, 2025 | Kristine Peterson director | AGrant or award Stock Option (right to buy)derivative | +15,700 | $0.00 | $0 | 15,700 | Mar 14, 2025 |
| Mar 13, 2025 | Lesley Russell director | AGrant or award Stock Option (right to buy)derivative | +15,700 | $0.00 | $0 | 15,700 | Mar 14, 2025 |
| Mar 13, 2025 | Terry Vance director | AGrant or award Stock Option (right to buy)derivative | +15,700 | $0.00 | $0 | 15,700 | Mar 14, 2025 |
| Mar 13, 2025 | Bruce L A Carter director | AGrant or award Stock Option (right to buy)derivative | +15,700 | $0.00 | $0 | 15,700 | Mar 14, 2025 |
| Feb 12, 2025 | Jay R. Luly President and CEO | AGrant or award Common Stock | +25,500 | $0.00 | $0 | 872,138 | Feb 14, 2025 |
| Feb 12, 2025 | Brendan Luu Chief Business Officer | AGrant or award Common Stock | +7,500 | $0.00 | $0 | 43,547 | Feb 14, 2025 |
| Feb 12, 2025 | Paul J Mellett Chief Fin. & Admin Officer | AGrant or award Common Stock | +7,500 | $0.00 | $0 | 99,210 | Feb 14, 2025 |
| Feb 12, 2025 | Yat Sun Or Chief Scientific Officer | AGrant or award Common Stock | +9,750 | $0.00 | $0 | 378,859 | Feb 14, 2025 |
| Feb 12, 2025 | Tara Lynn Kieffer Chief Product Strategy Officer | AGrant or award Common Stock | +7,500 | $0.00 | $0 | 36,805 | Feb 14, 2025 |
| Feb 12, 2025 | Scott T. Rottinghaus Chief Medical Officer | AGrant or award Common Stock | +9,750 | $0.00 | $0 | 27,668 | Feb 14, 2025 |
| Feb 12, 2025 | Brendan Luu Chief Business Officer | FTax withholding Common Stock | -3,326 | $5.59 | $19k | 40,221 | Feb 14, 2025 |
| Feb 12, 2025 | Tara Lynn Kieffer Chief Product Strategy Officer | FTax withholding Common Stock | -3,326 | $5.59 | $19k | 33,479 | Feb 14, 2025 |
| Feb 12, 2025 | Yat Sun Or Chief Scientific Officer | FTax withholding Common Stock | -4,324 | $5.59 | $24k | 374,535 | Feb 14, 2025 |
| Feb 12, 2025 | Paul J Mellett Chief Fin. & Admin Officer | FTax withholding Common Stock | -3,326 | $5.59 | $19k | 95,884 | Feb 14, 2025 |
| Feb 12, 2025 | Jay R. Luly President and CEO | FTax withholding Common Stock | -7,484 | $5.59 | $42k | 864,654 | Feb 14, 2025 |
| Feb 12, 2025 | Scott T. Rottinghaus Chief Medical Officer | FTax withholding Common Stock | -2,861 | $5.59 | $16k | 24,807 | Feb 14, 2025 |
| Feb 12, 2025 | Jay R. Luly President and CEO | POpen-market purchase Common Stock | +45,000 | $5.69 | $256k | 846,638 | Feb 12, 2025 |
| Dec 6, 2024 | Jay R. Luly President and CEO | SOpen-market sale Common Stock10b5-1 | -5,142 | $8.06 | $41k | 801,638 | Dec 10, 2024 |
| Dec 6, 2024 | Paul J Mellett Chief Fin. & Admin Officer | SOpen-market sale Common Stock10b5-1 | -2,591 | $8.06 | $21k | 91,710 | Dec 10, 2024 |
| Dec 6, 2024 | Yat Sun Or Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -2,591 | $8.06 | $21k | 369,109 | Dec 10, 2024 |
| Dec 6, 2024 | Scott T. Rottinghaus Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -866 | $8.06 | $6,980 | 17,918 | Dec 10, 2024 |
| Dec 6, 2024 | Brendan Luu Chief Business Officer | SOpen-market sale Common Stock10b5-1 | -2,283 | $8.06 | $18k | 36,047 | Dec 10, 2024 |
| Dec 6, 2024 | Tara Lynn Kieffer Chief Product Strategy Officer | SOpen-market sale Common Stock10b5-1 | -2,283 | $8.06 | $18k | 29,305 | Dec 10, 2024 |
| Dec 1, 2024 | Jay R. Luly President and CEO | FTax withholding Common Stock | -3,829 | $8.60 | $33k | 806,780 | Dec 3, 2024 |
| Dec 1, 2024 | Brendan Luu Chief Business Officer | FTax withholding Common Stock | -753 | $8.60 | $6,476 | 38,330 | Dec 3, 2024 |
| Dec 1, 2024 | Tara Lynn Kieffer Chief Product Strategy Officer | FTax withholding Common Stock | -753 | $8.60 | $6,476 | 31,588 | Dec 3, 2024 |
| Dec 1, 2024 | Yat Sun Or Chief Scientific Officer | FTax withholding Common Stock | -1,595 | $8.60 | $14k | 371,700 | Dec 3, 2024 |
| Dec 1, 2024 | Paul J Mellett Chief Fin. & Admin Officer | FTax withholding Common Stock | -1,595 | $8.60 | $14k | 94,301 | Dec 3, 2024 |
| Nov 27, 2024 | Jay R. Luly President and CEO | AGrant or award Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Nov 27, 2024 |
| Nov 27, 2024 | Paul J Mellett Chief Fin. & Admin Officer | AGrant or award Stock Option (right to buy)derivative | +81,000 | $0.00 | $0 | 81,000 | Nov 27, 2024 |
| Nov 27, 2024 | Yat Sun Or Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +87,000 | $0.00 | $0 | 87,000 | Nov 27, 2024 |
| Nov 27, 2024 | Scott T. Rottinghaus Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +87,000 | $0.00 | $0 | 87,000 | Nov 27, 2024 |
| Nov 27, 2024 | Tara Lynn Kieffer Chief Product Strategy Officer | AGrant or award Stock Option (right to buy)derivative | +81,000 | $0.00 | $0 | 81,000 | Nov 27, 2024 |
| Nov 27, 2024 | Brendan Luu Chief Business Officer | AGrant or award Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Nov 27, 2024 |
| Nov 27, 2024 | Matthew Paul Kowalsky Chief Legal Officer | AGrant or award Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Nov 27, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Bruce L A Carterdirector
- Mark G Folettadirector
- Yujiro S Hatadirector, ceo, president, officer
- Tara Lynn KiefferChief Product Strategy Officer
- Matthew Paul KowalskyChief Legal Officer
- Jay R. LulyPresident and CEO
- Brendan LuuChief Business Officer
- Paul J MellettChief Fin. & Admin Officer
- Yat Sun OrChief Scientific Officer
- Kristine Petersondirector
- Scott T. RottinghausChief Medical Officer
- Lesley Russelldirector
- Terry Vancedirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.